|
|
|
|
LEADER |
03431nmm a2200373 u 4500 |
001 |
EB000384632 |
003 |
EBX01000000000000000237684 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
130626 ||| eng |
020 |
|
|
|a 9783642136634
|
100 |
1 |
|
|a Rommel, Christian
|e [editor]
|
245 |
0 |
0 |
|a Phosphoinositide 3-kinase in Health and Disease
|h Elektronische Ressource
|b Volume 1
|c edited by Christian Rommel, Bart Vanhaesebroeck, Peter K. Vogt
|
250 |
|
|
|a 1st ed. 2011
|
260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 2011, 2011
|
300 |
|
|
|a X, 310 p. 29 illus., 23 illus. in color
|b online resource
|
505 |
0 |
|
|a PI3K – From the Bench to the Clinic and Back -- PI3K Book Introduction -- PDK1: The major transducer of PI 3-Kinase actions -- Protein Kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway -- Regulatory subunits of class IA PI3K -- The Regulation of Class IA PI 3-kinases by Inter-Subunit Interactions -- Phosphoinositide signalling pathways in metabolic regulation -- Role of RAS in the regulation of PI 3-kinase -- More than just kinases: The scaffolding function of PI3K -- PI3K signalling in neutrophils -- PI 3-kinase p110beta regulation of platelet integrin alphaIIbbeta3 -- PI3Ks in lymphocyte signalling and development -- PI3 kinase regulation of skeletal muscle hypertrophy and atrophy -- Taking PI3Kdelta and PI3Kgamma one step ahead – Dual active PI3Kdelta/gamma inhibitors for the treatment of immune-mediated inflammatory diseases -- Oncogenic Mutations of PIK3CA in Human Cancers -- Structural Effects of Oncogenic PI3Kalpha Mutations -- Comparing the roles of the p110alpha and p110beta isoforms of PI3K in signaling and cancer -- Phosphatidylinositol 3-kinase (PI3K): The oncoprotein -- AKT Signaling in Physiology and Disease -- Faithfull modeling of PTEN loss driven diseases in the mouse -- PI3K as a target for therapy in haematological malignancies -- Clinical development of Phosphatidylinositol-3 kinase pathway inhibitors -- New inhibitors of the PI3K-Akt-mTOR pathway: Insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs) -- Small molecule inhibitors of the PI3-kinase family -- Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance -- Subject index
|
653 |
|
|
|a Medicine / Research
|
653 |
|
|
|a Biology / Research
|
653 |
|
|
|a Human Physiology
|
653 |
|
|
|a Human physiology
|
653 |
|
|
|a Cancer
|
653 |
|
|
|a Biomedical Research
|
653 |
|
|
|a Cancer Biology
|
700 |
1 |
|
|a Vanhaesebroeck, Bart
|e [editor]
|
700 |
1 |
|
|a Vogt, Peter K.
|e [editor]
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
490 |
0 |
|
|a Current Topics in Microbiology and Immunology
|
028 |
5 |
0 |
|a 10.1007/978-3-642-13663-4
|
856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-13663-4?nosfx=y
|x Verlag
|3 Volltext
|
082 |
0 |
|
|a 616.994
|
082 |
0 |
|
|a 571.978
|
520 |
|
|
|a From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
|